Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [23]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13542 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Thymidine Phosphorylase Monoclonal Antibody (P-GF.44C)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-13542 targets Thymidine Phosphorylase in IHC (P) applications and shows reactivity with Human, mouse, and Rat samples. The MA5-13542 immunogen is recombinant full length human thymidine phosphorylase (TP/PD-ECGF) protein.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- P-GF.44C
- Vial size
- 500 µL
- Concentration
- 0.2 mg/mL
- Storage
- 4° C
Submitted references Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts.
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways.
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.
Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
Upregulation of thymidine phosphorylase in chronic glomerulonephritis and its role in tubulointerstitial injury.
H pylori status and angiogenesis factors in human gastric carcinoma.
H pylori status and angiogenesis factors in human gastric carcinoma.
Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma.
Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
Angiogenic growth factors in preinvasive breast disease.
Kim JY, Shin E, Kim JW, Lee HS, Lee DW, Kim SH, Lee JO, Kim YJ, Kim JH, Bang SM, Ahn SH, Park DJ, Lee JS, Lee JS, Kim HH, Lee KW
PloS one 2015;10(3):e0120324
PloS one 2015;10(3):e0120324
Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts.
Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C
Disease markers 2011;31(2):55-65
Disease markers 2011;31(2):55-65
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH
Cancer chemotherapy and pharmacology 2011 Sep;68(3):743-51
Cancer chemotherapy and pharmacology 2011 Sep;68(3):743-51
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Won YW, Park YH, Ahn MJ, Do IG, Ko YH, Park K
Annals of oncology : official journal of the European Society for Medical Oncology 2011 Feb;22(2):417-23
Annals of oncology : official journal of the European Society for Medical Oncology 2011 Feb;22(2):417-23
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH
British journal of cancer 2010 Sep 7;103(6):845-51
British journal of cancer 2010 Sep 7;103(6):845-51
Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways.
Chen CC, Chen LC, Liang Y, Tsang NM, Chang YS
Cellular signalling 2010 Jul;22(7):1132-42
Cellular signalling 2010 Jul;22(7):1132-42
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
Kim SJ, Han SW, Oh DY, Yi NJ, Kim YJ, Im SA, Yoon JH, Kang GH, Suh KS, Bang YJ, Jang JJ, Kim TY
Anticancer research 2010 Dec;30(12):5245-50
Anticancer research 2010 Dec;30(12):5245-50
Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.
Brockenbrough JS, Morihara JK, Hawes SE, Stern JE, Rasey JS, Wiens LW, Feng Q, Vesselle H
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2009 Nov;57(11):1087-97
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2009 Nov;57(11):1087-97
Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS.
Chi LM, Lee CW, Chang KP, Hao SP, Lee HM, Liang Y, Hsueh C, Yu CJ, Lee IN, Chang YJ, Lee SY, Yeh YM, Chang YS, Chien KY, Yu JS
Molecular & cellular proteomics : MCP 2009 Jul;8(7):1453-74
Molecular & cellular proteomics : MCP 2009 Jul;8(7):1453-74
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ
European journal of cancer (Oxford, England : 1990) 2009 Jul;45(11):1999-2006
European journal of cancer (Oxford, England : 1990) 2009 Jul;45(11):1999-2006
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Chihara Y, Fujimoto K, Miyake M, Hiasa Y, Hirao Y
Oncology reports 2009 Jul;22(1):23-8
Oncology reports 2009 Jul;22(1):23-8
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
Chihara Y, Fujimoto K, Miyake M, Hiasa Y, Hirao Y
Oncology reports 2009 Jul;22(1):23-8
Oncology reports 2009 Jul;22(1):23-8
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY
British journal of cancer 2009 Jan 27;100(2):298-304
British journal of cancer 2009 Jan 27;100(2):298-304
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D, Montie J, Sarkar FH, Shah RB, Hussain M
The Journal of urology 2008 Mar;179(3):911-5; discussion 915-6
The Journal of urology 2008 Mar;179(3):911-5; discussion 915-6
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM
Cancer chemotherapy and pharmacology 2008 Jun;62(1):77-84
Cancer chemotherapy and pharmacology 2008 Jun;62(1):77-84
Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C, Gebhardt K, Gruenberger B, Steinrueck V, Zommer H, Freudenthaler H, Roka S, Gruenberger T
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Apr 1;14(7):2065-74
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Apr 1;14(7):2065-74
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
Ranieri G, Grammatica L, Patruno R, Zito AF, Valerio P, Iacobellis S, Gadaleta C, Gasparini G, Ribatti D
Journal of cellular and molecular medicine 2007 Mar-Apr;11(2):362-8
Journal of cellular and molecular medicine 2007 Mar-Apr;11(2):362-8
Upregulation of thymidine phosphorylase in chronic glomerulonephritis and its role in tubulointerstitial injury.
Wang EH, Goh YB, Moon IS, Park CH, Lee KH, Kang SH, Kang CS, Choi YJ
Nephron. Clinical practice 2006;102(3-4):c133-42
Nephron. Clinical practice 2006;102(3-4):c133-42
H pylori status and angiogenesis factors in human gastric carcinoma.
Mangia A, Chiriatti A, Ranieri G, Abbate I, Coviello M, Simone G, Zito FA, Montemurro S, Rucci A, Di Leo A, Tommasi S, Berloco P, Xu JM, Paradiso A
World journal of gastroenterology 2006 Sep 14;12(34):5465-72
World journal of gastroenterology 2006 Sep 14;12(34):5465-72
H pylori status and angiogenesis factors in human gastric carcinoma.
Mangia A, Chiriatti A, Ranieri G, Abbate I, Coviello M, Simone G, Zito FA, Montemurro S, Rucci A, Di Leo A, Tommasi S, Berloco P, Xu JM, Paradiso A
World journal of gastroenterology 2006 Sep 14;12(34):5465-72
World journal of gastroenterology 2006 Sep 14;12(34):5465-72
Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma.
Stavropoulos NE, Bouropoulos C, Ioachim E, Michael M, Hastazeris K, Tsimaris I, Kalogeras D, Liamis Z, Kafarakis V, Stefanaki S, Malamou-Mitsi V
International urology and nephrology 2005;37(1):55-60
International urology and nephrology 2005;37(1):55-60
Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benkö T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J, Stift A
Cancer 2003 Nov 15;98(10):2291-301
Cancer 2003 Nov 15;98(10):2291-301
Angiogenic growth factors in preinvasive breast disease.
Heffelfinger SC, Miller MA, Yassin R, Gear R
Clinical cancer research : an official journal of the American Association for Cancer Research 1999 Oct;5(10):2867-76
Clinical cancer research : an official journal of the American Association for Cancer Research 1999 Oct;5(10):2867-76
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of MDA-MB-231 (Lane 1), A-431 (Lane 2), U2OS (Lane 3) and HeLa (Lane 4). The blots were probed with Thymidine Phosphorylase Mouse monoclonal Antibody (Product # MA5-13542, 0.5 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). A 50 kDa band corresponding to Thymidine Phosphorylase was observed across the cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0322BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5% skimmed milk. Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast carcinoma stained with Thymidine Phosphorylase antibody using peroxidase-conjugate and AEC chromogen. Note nuclear and cytoplasmic staining of tumor cells.
